Entity Central Index Key Document and entity information. Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Asset acquisition accrued purchase price payable. Statement Of Financial Position [Abstract] ASSETS Assets [Abstract] CURRENT ASSETS Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Prepaid expenses Prepaid Expense Current Other current assets Other Assets Current Short term investments Held To Maturity Securities Current TOTAL CURRENT ASSETS Assets Current Property and equipment, net Property Plant And Equipment Net Intangible assets, net Intangible Assets Net Excluding Goodwill Investments Held To Maturity Securities Noncurrent Other assets Other Assets Miscellaneous Noncurrent TOTAL ASSETS Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities And Stockholders Equity [Abstract] CURRENT LIABILITIES Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued expenses Accrued Liabilities Current Due to Novartis Asset Acquisition Accrued Purchase Price Payable Accrued payroll and benefits Employee Related Liabilities Current Deferred revenue Deferred Revenue Current Derivative liabilities Derivative Liabilities Current Capital lease obligation Capital Lease Obligations Current Notes payable Notes Payable Current Other current liabilities Other Liabilities Current TOTAL CURRENT LIABILITIES Liabilities Current LONG-TERM LIABILITIES Liabilities Noncurrent [Abstract] Capital lease obligation, net of current portion Capital Lease Obligations Noncurrent Contingent consideration obligations Business Combination Contingent Consideration Liability Other non-current liabilities Other Liabilities Noncurrent TOTAL LONG-TERM LIABILITIES Liabilities Noncurrent Commitments and contingencies Commitments And Contingencies STOCKHOLDERS’ EQUITY Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract] Arrowhead Research Corporation stockholders' equity: Stockholders Equity [Abstract] Preferred stock, $0.001 par value; 5,000,000 shares authorized; 15,652 and 18,300 shares issued and outstanding as of March 31, 2015 and September 30, 2014, respectively Preferred Stock Value Common stock, $0.001 par value; 145,000,000 shares authorized; 59,435,862 and 54,656,936 shares issued and outstanding as of March 31, 2015 and September 30, 2014, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated deficit Retained Earnings Accumulated Deficit Total Arrowhead Research Corporation stockholders' equity Stockholders Equity Noncontrolling interest Minority Interest TOTAL STOCKHOLDERS’ EQUITY Stockholders Equity Including Portion Attributable To Noncontrolling Interest TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities And Stockholders Equity Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares issued Preferred Stock Shares Issued Preferred stock, shares outstanding Preferred Stock Shares Outstanding Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding The amount of purchased research and development assets that are acquired in asset acquisition have no alternative future use and are therefore written off in the period of acquisition. Income Statement [Abstract] REVENUE Revenues OPERATING EXPENSES Operating Expenses [Abstract] Research and development Research And Development Expense Acquired in-process research and development Acquired In Process Research And Development Salaries and payroll-related costs Labor And Related Expense General and administrative expenses General And Administrative Expense Stock-based compensation Share Based Compensation Depreciation and amortization Depreciation And Amortization TOTAL OPERATING EXPENSES Operating Expenses OPERATING LOSS Operating Income Loss OTHER INCOME (EXPENSE) Nonoperating Income Expense [Abstract] Equity in income (loss) of unconsolidated affiliates Income Loss From Equity Method Investments Gain (loss) on sale of fixed assets, net Gain Loss On Sale Of Property Plant Equipment Interest income (expense), net Interest Income Expense Nonoperating Net Change in value of derivatives Unrealized Gain Loss On Derivatives Other income (expense) Other Nonoperating Income Expense TOTAL OTHER INCOME (EXPENSE) Nonoperating Income Expense LOSS BEFORE INCOME TAXES Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Provision for income taxes Income Tax Expense Benefit NET LOSS Profit Loss Net loss attributable to noncontrolling interests Net Income Loss Attributable To Noncontrolling Interest NET LOSS ATTRIBUTABLE TO ARROWHEAD Net Income Loss NET LOSS PER SHARE ATTRIBUTABLE TO ARROWHEAD SHAREHOLDERS - BASIC AND DILUTED: Earnings Per Share Basic And Diluted Weighted average shares outstanding - basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX Comprehensive Income Net Of Tax [Abstract] Foreign Currency Translation Adjustments Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax COMPREHENSIVE LOSS ATTRIBUTABLE TO ARROWHEAD Comprehensive Income Net Of Tax Stock issued during period value exercise of warrants. Stock issued during period shares exercise of warrants. Exchange rights exercised during period value. Exchange rights exercised during period shares. Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Preferred Stock Preferred Stock [Member] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid In Capital [Member] Accumulated Other Comprehensive Income (loss) Accumulated Other Comprehensive Income [Member] Accumulated Deficit during Development Stage Accumulated Deficit During Development Stage [Member] Noncontrolling Interest Noncontrolling Interest [Member] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Issued at five dollar and eighty six cents per share. Common stock issued @ $5.86 Issued At Five Dollar And Eighty Six Cents Per Share [Member] Issued at eighteen dollar and ninety five cents per share. Common stock issued @ $18.95 Issued At Eighteen Dollar And Ninety Five Cents Per Share [Member] Preferred stock issued at thousand dollar per share. Preferred stock issued at $1,000 per share Preferred Stock Issued At Thousand Dollar Per Share [Member] Issued to Galloway. Common Stock Issued to Galloway Issued To Galloway [Member] Issued to Novartis at seven dollar and fifty three cents per share. Issued To Novartis At Seven Dollar And Fifty Three Cents Per Share Issued To Novartis At Seven Dollar And Fifty Three Cents Per Share [Member] Statement [Line Items] Statement [Line Items] Beginning Balance Amount Beginning Balance Shares Shares Issued Exercise of warrants, Amount Stock Issued During Period Value Exercise Of Warrants Exercise of warrants Stock Issued During Period Shares Exercise Of Warrants Stock options exercised, Amount Stock Issued During Period Value Stock Options Exercised Stock options exercised Stock Issued During Period Shares Stock Options Exercised Stock-based compensation Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Exercise of exchange rights, Amount Exchange Rights Exercised During Period Value Exercise of exchange rights, Shares Exchange Rights Exercised During Period Shares Stock issuances Stock Issued During Period Value New Issues Stock issuances, Shares Stock Issued During Period Shares New Issues Settlements related to derivative liability Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax Preferred stock converted to common stock, Amount Stock Issued During Period Value Conversion Of Units Preferred stock converted to common stock, Shares Stock Issued During Period Shares Conversion Of Units Deconsolidation of Calando Pharmaceuticals, Inc. Noncontrolling Interest Decrease From Deconsolidation Common stock-RSU vesting, Amount Stock Issued During Period Value Restricted Stock Award Gross Common stock-RSU vesting, Shares Stock Issued During Period Shares Restricted Stock Award Gross Total Other Comprehensive Income (loss) Other Comprehensive Income Loss Net Of Tax Net loss Ending Balance Amount Ending Balance Shares Common stock issued, price per share Shares Issued Price Per Share Proceeds from exercise of warrants and stock options. Common stock issued to Novartis for asset acquisition. Statement Of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract] (Gain) loss on disposal of fixed assets Change in value of derivatives Amortization of note premiums Amortization Of Debt Discount Premium Non-controlling interest Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Receivables Increase Decrease In Receivables Other receivables Increase Decrease In Other Receivables Other current assets Increase Decrease In Other Current Assets Accounts payable Increase Decrease In Accounts Payable Accrued expenses Increase Decrease In Accrued Liabilities Other Increase Decrease In Other Operating Liabilities NET CASH USED IN OPERATING ACTIVITIES Net Cash Provided By Used In Operating Activities Continuing Operations CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract] Cash paid for acquisitions Payments To Acquire Assets Investing Activities Purchases of property and equipment Payments To Acquire Property Plant And Equipment Proceeds from sale of fixed assets Proceeds From Sale Of Property Plant And Equipment Purchase of marketable securities Payments To Acquire Marketable Securities Proceeds from sale of marketable securities Proceeds From Sale And Maturity Of Marketable Securities NET CASH USED IN INVESTING ACTIVITIES Net Cash Provided By Used In Investing Activities Continuing Operations CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract] Principal payments on capital leases and notes payable Repayments Of Long Term Capital Lease Obligations Proceeds from issuance of common stock and preferred stock, net Proceeds From Issuance Or Sale Of Equity Proceeds from the exercise of warrants and stock options Proceeds From Exercise Of Warrants And Stock Options NET CASH PROVIDED BY FINANCING ACTIVITIES Net Cash Provided By Used In Financing Activities Continuing Operations NET INCREASE (DECREASE) IN CASH Cash And Cash Equivalents Period Increase Decrease CASH AT BEGINNING OF PERIOD CASH AT END OF PERIOD Supplementary disclosures: Supplemental Cash Flow Information [Abstract] Interest paid Interest Paid Common stock issued to Novartis for asset acquisition Common Stock Issued For Asset Acquisition Accounting Policies [Abstract] Organization and Significant Accounting Policies Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block] Asset acquisition. Asset acquisition. Asset Acquisition [Abstract] Acquisitions Asset Acquisition Disclosure [Text Block] Property Plant And Equipment [Abstract] Property and Equipment Property Plant And Equipment Disclosure [Text Block] Investments All Other Investments [Abstract] Investments Cost And Equity Method Investments Disclosure [Text Block] Goodwill And Intangible Assets Disclosure [Abstract] Intangible Assets Intangible Assets Disclosure [Text Block] Equity [Abstract] Stockholders' Equity Stockholders Equity Note Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stock-Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Nature of Business Business Description And Accounting Policies [Text Block] Liquidity Liquidity Disclosure [Text Block] Principles of Consolidation Consolidation Policy [Text Block] Basis of presentation and use of estimates. Basis of Presentation and Use of Estimates Basis Of Presentation And Use Of Estimates Policy [Text Block] Cash and Cash Equivalents Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy Concentration of Credit Risk Concentration Risk Credit Risk Investments Investment Policy [Text Block] Property and Equipment Property Plant And Equipment Policy [Text Block] Intangible Assets subject to amortization Goodwill And Intangible Assets Policy [Text Block] In-Process Research & Development (IPR&D) In Process Research And Development Policy Disclosure of accounting policy for contingent consideration obligations related to acquisitions. Contingent Consideration Contingent Consideration Policy [Text Block] Revenue Recognition Revenue Recognition Policy [Text Block] Allowance for Doubtful Accounts Trade And Other Accounts Receivable Policy Research and Development Research And Development Expense Policy Earnings (Loss) per Share Earnings Per Share Policy [Text Block] Stock-Based Compensation Share Based Compensation Option And Incentive Plans Policy Derivative Assets and Liabilities Derivatives Policy [Text Block] Income Taxes Income Tax Policy [Text Block] Summary of Estimated Fair Values at Date of Acquisition Schedule Of Recognized Identified Assets Acquired And Liabilities Assumed Table [Text Block] Summary of purchase consideration. Summary of Purchase Consideration Summary Of Purchase Consideration Table [Text Block] Summary of Property and Equipment Property Plant And Equipment [Text Block] Summary of Short and Long-term Investments Held To Maturity Securities [Text Block] Schedule of Intangible Assets Schedule Of Intangible Assets And Goodwill Table [Text Block] Summary of Information About Warrants Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block] Leases [Abstract] Future Minimum Lease Payments Under Capitalized Leases Schedule Of Future Minimum Lease Payments For Capital Leases Table [Text Block] Future Minimum Lease Payments Under Operating Leases Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block] Summarized Information about Stock Options Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Assumptions Used to Value Stock Options Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Summary of Share Activity Related to Restricted Stock Units Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table] Financial Instrument Financial Instrument [Axis] Financial Instruments Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain] Warrant Warrant [Member] Liability Class Fair Value By Liability Class [Axis] Fair Value by Liability Class Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain] Exchange rights. Exchange rights Exchange Rights [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block] Assumptions Used in Valuing Derivative Liabilities Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques Table [Text Block] Reconciliation of Derivative Liability Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block] Change in Fair Value of Contingent Consideration Obligations Schedule Of Business Acquisitions By Acquisition Contingent Consideration [Text Block] Schedule Of Investments [Table] Schedule Of Investments [Table] Asset acquisition. Asset Acquisition Asset Acquisition [Axis] Asset acquisition. Asset Acquisition Asset Acquisition [Domain] Novartis. Novartis Novartis [Member] Summary of Investments, Other than Investments in Related Parties, by Type Summary Of Investments Other Than Investments In Related Parties By Type [Axis] Summary of Investments, by Type Summary Of Investments By Type [Domain] Commercial bonds Bonds [Member] Range Range [Axis] Range Range [Member] Minimum Minimum [Member] Maximum Maximum [Member] Schedule Of Investments [Line Items] Schedule Of Investments [Line Items] Cash to fund operations Maturity description Debt Instrument Maturity Date Description Investments Held To Maturity Securities Net increase (decrease) in cash Cash outflow related to continuing operating activities Cash payment for acquisition Capital expenditures Restricted Cash Restricted Cash And Cash Equivalents Amount insured in FDIC per account Cash F D I C Insured Amount Property, Plant and Equipment, Useful Life Property Plant And Equipment Useful Life Asset acquisition. Asset acquisition. Asset Acquisition [Table] Asset Acquisition [Table] Subsequent Event Type Subsequent Event Type [Axis] Subsequent Event Type Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Asset Acquisition [Line Items] Asset Acquisition [Line Items] Value of Shares Issued to Novartis Stock Issued During Period Shares Acquisitions Obligation to pay royalties. Obligation to pay royalties Obligation To Pay Royalties Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, resulting from asset acquisition. Finite-Lived Intangible Assets by Major Class Finite Lived Intangible Assets By Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name Finite Lived Intangible Assets Major Class Name [Domain] Patents [Member] Patents [Member] License. License [Member] License [Member] Assets acquired Assets Acquired Finite Lived Intangible Assets Asset Acquisition Consideration Transferred. Value of Shares Issued to Novartis during the three months ended March 31, 2015 Stock Issued During Period Value Acquisitions Total purchase consideration Asset Acquisition Consideration Transferred Research equipment. Computers, office equipment and furniture Furniture And Fixtures Gross Research equipment Research Equipment Software Capitalized Computer Software Gross Leasehold improvements Leasehold Improvements Gross Total gross fixed assets Property Plant And Equipment Gross Less: Accumulated depreciation and amortization Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Property and equipment, net Schedule Of Held To Maturity Securities [Table] Schedule Of Held To Maturity Securities [Table] Major Types of Debt and Equity Securities Major Types Of Debt And Equity Securities [Axis] Major Types of Debt and Equity Securities Major Types Of Debt And Equity Securities [Domain] Commercial notes due within one year. Commercial Notes Due Within One Year Commercial Notes Due Within One Year [Member] Commercial notes due after one year through two years. Commercial Notes Due After One Year Through Two Years Commercial Notes Due After One Year Through Two Years [Member] Schedule Of Held To Maturity Securities [Line Items] Schedule Of Held To Maturity Securities [Line Items] Gross Unrealized Gains Held To Maturity Securities Accumulated Unrecognized Holding Gain Gross Unrealized Losses Held To Maturity Securities Accumulated Unrecognized Holding Loss Fair Value Held To Maturity Securities Fair Value Commercial notes (due within one year), amortized cost Commercial notes (due after one year through two years), amortized cost Total Schedule Of Finite Lived Intangible Assets [Table] Schedule Of Finite Lived Intangible Assets [Table] Novartis RNAi. Novartis RNAi [Member] Novartis R N Ai [Member] Roche Madison. Roche Madison [Member] Roche Madison [Member] Licensing Agreements Licensing Agreements [Member] Finite Lived Intangible Assets [Line Items] Finite Lived Intangible Assets [Line Items] Amortization period of intangible assets Finite Lived Intangible Asset Useful Life Finite-lived intangible assets, accumulated amortization Finite Lived Intangible Assets Accumulated Amortization Amortization expense Amortization Of Intangible Assets Amortization of license agreements remainder of fiscal year 2015 Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year Amortization of license agreements in 2016 Finite Lived Intangible Assets Amortization Expense Next Twelve Months Amortization of license agreements in 2017 Finite Lived Intangible Assets Amortization Expense Year Two Amortization of license agreements in 2018 Finite Lived Intangible Assets Amortization Expense Year Three Amortization of license agreements in 2019 Finite Lived Intangible Assets Amortization Expense Year Four Amortization of license agreements in 2020 Finite Lived Intangible Assets Amortization Expense Year Five Amortization of license agreements, thereafter Finite Lived Intangible Assets Amortization Expense After Year Five Assets acquired indefinite lived intangible assets. Indefinite lived intangible assets amortization. Intangible Assets Net Excluding Goodwill [Abstract] Intangible assets not subject to amortization, beginning balance Indefinite Lived Intangible Assets Excluding Goodwill Intangible assets not subject to amortization, Impairment Impairment Of Intangible Assets Indefinitelived Excluding Goodwill Intangible assets not subject to amortization, Acquisition of Novartis RNAi Assets Assets Acquired Indefinite Lived Intangible Assets Intangible assets not subject to amortization, Amortization Indefinite Lived Intangible Assets Amortization Intangible assets not subject to amortization, ending balance Intangible assets subject to amortization, beginning balance Finite Lived Intangible Assets Net Intangible assets subject to amortization, Impairment Impairment Of Intangible Assets Finitelived Intangible assets subject to amortization, Acquisition of Novartis RNAi Assets Intangible assets subject to amortization, Amortization Intangible assets subject to amortization, ending balance Total Intangible assets, beginning balance Total Intangible assets, Impairment Impairment Of Intangible Assets Excluding Goodwill Total Intangible assets, ending balance Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Two thousand four equity incentive plan two thousand thirteen equity incentive plan and inducement grants. 2004 Equity Incentive Plan, 2013 Equity Incentive Plan, and Inducement Grants Two Thousand Four Equity Incentive Plan Two Thousand Thirteen Equity Incentive Plan And Inducement Grants [Member] Series C Preferred Stock Series C Preferred Stock [Member] Class Of Stock [Line Items] Class Of Stock [Line Items] Capital stock authorized for issuance Capital Units Authorized Common stock equivalent of preferred stock shares upon conversion. Common stock equivalent of preferred stock Common Stock Equivalent Of Preferred Stock Shares Upon Conversion Common Stock, Share reserve for issuance Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Threshold percentage of common stock ownership upon preferred stock conversion. Threshold percentage of common stock ownership upon preferred stock conversion Threshold Percentage Of Common Stock Ownership Upon Preferred Stock Conversion Conversion price per share. Aggregate price of issuance or Sale of equity. Sale of stock, price per share Sale Of Stock Price Per Share Conversion price Conversion Price Per Share Aggregate price on issuance or Sale of equity Aggregate Price On Issuance Or Sale Of Equity Proceeds from issuance of common stock, net Proceeds From Issuance Of Common Stock Remaining life of warrant. Class Of Warrant Or Right [Table] Class Of Warrant Or Right [Table] Class of Warrant or Right Class Of Warrant Or Right [Axis] Class of Warrant or Right Class Of Warrant Or Right [Domain] Warrant one. Warrant 1 Warrant One [Member] Warrant two. Warrant 2 Warrant Two [Member] Warrant three. Warrant 3 Warrant Three [Member] Warrant four. Warrant 4 Warrant Four [Member] Warrant five. Warrant 5 Warrant Five [Member] Warrant six. Warrant 6 Warrant Six [Member] Warrant seven. Warrant 7 Warrant Seven [Member] Warrant eight. Warrant 8 Warrant Eight [Member] Class Of Warrant Or Right [Line Items] Class Of Warrant Or Right [Line Items] Exercise prices Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 Warrants outstanding Class Of Warrant Or Right Outstanding Remaining Life in Years Remaining Life Of Warrant Percentage of increase in annual rental cost. Other Commitments [Table] Other Commitments [Table] Property Subject to or Available for Operating Lease Property Subject To Or Available For Operating Lease [Axis] Property Subject to or Available for Operating Lease Property Subject To Or Available For Operating Lease [Domain] Corporate Headquarters in Pasadena Corporate Headquarters In Pasadena Corporate Headquarters In Pasadena [Member] Research facility in Madison. Research Facility in Madison Research Facility In Madison [Member] Other Commitments [Line Items] Other Commitments [Line Items] Rental expense Lease And Rental Expense Operating lease expiration date Lease Expiration Date1 Percentage of increase in annual rental cost Percentage Of Increase In Annual Rental Cost Other rental expenses. Payments under capital lease. Leased facility expense. Other rental expenses including common area maintenance and real estate taxes Other Rental Expenses Utilities costs per month Utilities Costs Monthly payments under capital lease Payments Under Capital Lease Total Monthly Facility Expense - Madison facility Leased Facility Expense Facility and equipment rent expense. Facility and equipment rent expense Facility And Equipment Rent Expense 2015 (remainder of) Capital Leases Future Minimum Payments Remainder Of Fiscal Year 2016 Capital Leases Future Minimum Payments Due Current 2017 Capital Leases Future Minimum Payments Due In Two Years 2018 Capital Leases Future Minimum Payments Due In Three Years 2019 Capital Leases Future Minimum Payments Due In Four Years 2020 and thereafter Capital Leases Future Minimum Payments Due Thereafter Less interest Capital Leases Future Minimum Payments Interest Included In Payments Principal Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments 2015 (remainder of) Operating Leases Future Minimum Payments Remainder Of Fiscal Year 2016 Operating Leases Future Minimum Payments Due Current 2017 Operating Leases Future Minimum Payments Due In Two Years 2018 Operating Leases Future Minimum Payments Due In Three Years 2019 Operating Leases Future Minimum Payments Due In Four Years 2020 and thereafter Operating Leases Future Minimum Payments Due Thereafter Total Operating Leases Future Minimum Payments Due Provision for recorded liabilities Retained Earnings Appropriated Future commitments Purchase Obligation Commitments expected to be incurred in fiscal 2015 Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year Commitments expected to be incurred beyond fiscal 2015 Purchase Obligation Due In Next Twelve Months Share based compensation arrangement by share based payment award inducement grants. Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Two thousands four equity incentive plan. 2004 Equity Incentive Plan Two Thousands Four Equity Incentive Plan [Member] Two thousands thirteen incentive plan. 2013 Incentive Plan Two Thousands Thirteen Incentive Plan [Member] Outside of equity compensation plans. Outside Of Equity Compensation Plans Outside Of Equity Compensation Plans [Member] Two thousands stock option plan. 2000 Stock Option Plan Two Thousands Stock Option Plan [Member] Award Type Award Type [Axis] Equity Award Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Employee Stock Option Employee Stock Option [Member] Restricted Stock Units (RSUs) Restricted Stock Units R S U [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Shares reserve for issuance Common Stock Capital Shares Reserved For Future Issuance Number of Options Outstanding Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Number of restricted stock units outstanding, granted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Number of restricted stock units outstanding Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number Number of Options Outstanding, Granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Units granted outside of Equity Incentive plans Share Based Compensation Arrangement By Share Based Payment Award Inducement Grants Stock options outstanding expired Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period Number of Options Outstanding, beginning balance Number of Options Outstanding, Cancelled Number of Options Outstanding, Exercised Number of Options Outstanding, ending balance Number of Options Outstanding, Exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Weighted Average Exercise Price Per Share, beginning balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Weighted Average Exercise Price Per Share, Granted Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Weighted Average Exercise Price Per Share, Cancelled Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price Weighted Average Exercise Price Per Share, Exercised Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Weighted Average Exercise Price Per Share, ending balance Weighted Average Exercise Price Per Share, Exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Weighted Average Remaining Contractual Term Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Weighted Average Remaining Contractual Term, Exercisable Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Aggregate Intrinsic Value, Exercisable Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 Stock-based compensation expense Allocated Share Based Compensation Expense Share based compensation arrangement by share based payment award options grants in period fair value. Fair value of the options granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value Intrinsic value of options exercised Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value Unrecognized pre-tax compensation expense Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options Weighted average period to recognize pre-tax compensation expense Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Dividend yield Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Risk-free interest rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Risk-free interest rate, minimum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum Risk-free interest rate, maximum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum Volatility Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Expected life (in years) Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 Weighted average grant date fair value per share of options granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Share-based compensation, description Share Based Compensation Arrangement By Share Based Payment Award Description Shares, Unvested, beginning of period Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number Shares, Vested Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Shares, Forfeited Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Shares, Unvested, End of period Weighted average grant date fair value, beginning balance Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Weighted average grant date fair value, Granted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value Weighted average grant date fair value, Vested Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Weighted average grant date fair value, Forfeited Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value Weighted average grant date fair value, ending balance Unrecognized pre-tax compensation expense Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Measurement Frequency Fair Value By Measurement Frequency [Axis] Fair Value, Measurement Frequency Fair Value Measurement Frequency [Domain] Fair Value, Measurements, Recurring Fair Value Measurements Recurring [Member] Fair Value, Hierarchy Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy Fair Value Measurements Fair Value Hierarchy [Domain] Level 1 Fair Value Inputs Level1 [Member] Level 2 Fair Value Inputs Level2 [Member] Level 3 Fair Value Inputs Level3 [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Cash and cash equivalents Cash And Cash Equivalents Fair Value Disclosure Acquisition-related contingent consideration obligations Fair value measurements disclosure. Fair value measurements disclosure. Fair Value Measurements Disclosure [Table] Fair Value Measurements Disclosure [Table] Two thousand ten warrant. 2010 Warrants Two Thousand Ten Warrant [Member] Two thousand twelve warrant. 2012 Warrants Two Thousand Twelve Warrant [Member] Two thousand thirteen warrant. 2013 Warrants Two Thousand Thirteen Warrant [Member] Ablaris Therapeutics. Ablaris Therapeutics Ablaris Therapeutics [Member] Fair Value Measurements Disclosure [Line Items] Fair Value Measurements Disclosure [Line Items] Total investments Fair value of investment Warrants issued to acquire common stock. Warrants issued to acquire Common Stock Warrants Issued To Acquire Common Stock Non-cash gain (loss) from change in fair value of the derivative liability Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings Risk-free interest rate Fair Value Assumptions Risk Free Interest Rate Expected life Fair Value Assumptions Expected Term Dividend yield Fair Value Assumptions Expected Dividend Rate Volatility Fair Value Assumptions Expected Volatility Rate Value, Beginning balance Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value Issuance of instruments Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues Change in value Net settlements Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements Value, Ending balance Term of exchange rights. Exchange right convertible conversion ratio for first year. Exchange right convertible conversion ratio for two year. Exchange right convertible conversion ratio for three year. Exchange right convertible conversion ratio for four year. Exchange right convertible conversion ratio for five year. Number of exchange right are sold. Duration of exchange rights Term Of Exchange Rights Exchange right convertible conversion ratio for first year Exchange Right Convertible Conversion Ratio For First Year Exchange right convertible conversion ratio for second year Exchange Right Convertible Conversion Ratio For Two Year Exchange right convertible conversion ratio for third year Exchange Right Convertible Conversion Ratio For Three Year Exchange right convertible conversion ratio for fourth year Exchange Right Convertible Conversion Ratio For Four Year Exchange right convertible conversion ratio for fifth year and beyond Exchange Right Convertible Conversion Ratio For Five Year Number of exchange right sold Number Of Exchange Right Are Sold Business combination purchase price contingent consideration fair value. Business combination contingent consideration payments. Business combination fair value of change in contingent consideration. Business Combinations [Abstract] Business Combinations [Abstract] Contingent consideration obligations, Beginning balance Purchase price contingent consideration Business Combination Purchase Price Contingent Consideration Fair Value Contingent consideration payments Business Combination Contingent Consideration Payments Change in fair value of contingent consideration Business Combination Fair Value Of Change In Contingent Consideration Contingent consideration obligations, Ending balance